vimarsana.com

Page 4 - விற்பனை ப்ர்யாக்டிஸஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New Jersey Rejects Bogus Exclusion Of FDA Device Clearance Evidence - Food, Drugs, Healthcare, Life Sciences

New Jersey Rejects Bogus Exclusion Of FDA Device Clearance Evidence - Food, Drugs, Healthcare, Life Sciences
mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.

Cornerstone Research Announces Michael Topper as New Board of Directors Chair

Cornerstone Research Announces Michael Topper as New Board of Directors Chair Share Article MENLO PARK, Calif. (PRWEB) February 19, 2021 Cornerstone Research, a leading provider of economic and financial consulting and expert testimony, announced today that Senior Vice President Michael D. Topper has been elected to a four-year term as chair of the firm’s board of directors. A leading antitrust and competition economist, Topper has more than 25 years of experience in antitrust merger review, complex business litigation, and regulatory proceedings. A longtime member of Cornerstone Research’s board of directors and executive committee, he also served as head or cohead of the firm’s antitrust and competition practice from 2004 to 2015, and as head of the Silicon Valley office from 2012 to 2017.

FINRA Issues 2021 Report on Examination and Risk Monitoring Program | Epstein Becker & Green

FINRA 2021 Report on Examination and Risk Monitoring Program

Friday, February 5, 2021 The recently issued 2021 Report on FINRA’s Examination and Risk Monitoring Program (the “Report”) replaces, and combines, two previously published FINRA reports – The Report on Examination Findings and Observations as well as the Risk Monitoring and Examination Program Priorities Letter. The Report addresses key regulatory topics in four categories: (1) Firm Operations; (2) Communications and Sales Practices; (3) Market Integrity; and (4) Financial Management. In particular, FINRA identified the following issues that impact many member firms. Regulation Best Interest (Reg BI) and Form CRS FINRA noted that in 2021 it intends to expand the scope of its review and testing in this area to engage in a more comprehensive review of firm processes, practices and conduct. FINRA provided a list of considerations its staff will use when examining a firm for compliance with Reg BI and Form CRS, and firms should make sure they have addressed those c

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.